Bioengineered Myometrial Tissue for Uterine Reconstruction

Abstract

Bioengineered myometrial tissue represents a transformative approach to uterine reconstruction, addressing significant clinical challenges in reproductive medicine and gynecologic surgery. Current surgical interventions for uterine defects, such as myomectomy, hysterectomy, or uterine transplantation, face limitations including donor scarcity, immunological mismatches, and variable long-term outcomes. Tissue engineering leverages advances in biomaterials, stem cell technology, and regenerative medicine to provide personalized, functional myometrial constructs capable of restoring uterine anatomy and function. This review synthesizes recent evidence on the development, clinical application, and future prospects of bioengineered myometrial tissue, with a focus on scientific mechanisms, clinical outcomes, and integration with existing guidelines.

Introduction

Uterine defects and loss of myometrial integrity, resulting from congenital anomalies, surgical excision, trauma, or disease, significantly impact fertility, pregnancy outcomes, and women's health. Traditional reconstructive techniques often fail to replicate the dynamic contractile and endocrine functions of native myometrium. The emergence of bioengineered myometrial tissue offers new promise for uterine reconstruction, enabling restoration of form and function. This article reviews the scientific foundation, clinical applications, and evolving landscape of bioengineered myometrial constructs, aiming to inform practitioners, surgeons, and researchers on this rapidly advancing field.

Epidemiology / Disease Burden

Uterine defects requiring reconstruction are encountered in a variety of clinical settings. Uterine fibroids are the most common benign tumors in women of reproductive age, with a prevalence of up to 70% by age 50. Surgical myomectomy or extensive fibroid excision can compromise myometrial integrity, leading to impaired fertility or uterine rupture risk. Congenital uterine anomalies, such as Mayer-Rokitansky-Küster-Hauser syndrome, affect approximately 1 in 4,500 female births and often necessitate reconstructive interventions. Uterine trauma, adenomyosis, and malignancy further contribute to the disease burden. Globally, the unmet need for effective uterine reconstruction is compounded by limited access to transplantation and the high morbidity associated with traditional approaches.

Pathophysiology

The myometrium, composed of smooth muscle cells interspersed with connective tissue and vasculature, plays a crucial role in menstruation, pregnancy, and parturition. Loss or disruption of myometrial tissue impairs uterine contractility, integrity, and endocrine signaling. The pathophysiological sequelae include increased risk of uterine rupture, infertility, abnormal uterine bleeding, and adverse pregnancy outcomes. Restoration of functional myometrial architecture is thus critical for reproductive and overall gynecologic health.

Risk Factors

Risk factors for myometrial defects include prior uterine surgeries (myomectomy, cesarean section), uterine trauma, congenital anomalies, infection, and iatrogenic injury. Chronic inflammatory states, such as endometriosis or adenomyosis, can also weaken the myometrial wall. Fertility preservation efforts in oncologic patients and those with severe uterine adhesions or Asherman's syndrome represent additional at-risk populations for myometrial loss and the need for reconstruction.

Clinical Features

Patients with myometrial defects may present with infertility, recurrent pregnancy loss, abnormal uterine bleeding, pelvic pain, or complications during pregnancy such as uterine rupture or preterm labor. The clinical presentation often depends on the extent, location, and etiology of the myometrial loss. In severe cases, complete uterine factor infertility may be diagnosed, necessitating advanced reconstructive strategies.

Diagnosis

Diagnosis is based on a combination of clinical history, gynecologic examination, and advanced imaging. Transvaginal ultrasound and magnetic resonance imaging (MRI) provide detailed visualization of myometrial architecture, thickness, and defects. Hysteroscopy may be used for direct visualization of the uterine cavity, aiding in the assessment of intrauterine adhesions and scarring. Biopsy and histopathology can further elucidate the etiology and extent of myometrial compromise.

Treatment & Management

Current management options include surgical repair (metroplasty), uterine transplantation, and conservative approaches for mild defects. However, these interventions are limited by donor availability, immunosuppression risks, surgical complications, and variable functional outcomes. Bioengineered myometrial tissue seeks to overcome these challenges by providing autologous or allogeneic constructs tailored to patient-specific defects. Scaffold-based approaches utilizing biocompatible polymers, decellularized matrices, and 3D bioprinting are being investigated to promote cellular integration and vascularization. Stem cell-derived smooth muscle cells seeded onto scaffolds have demonstrated contractile functionality and hormone responsiveness in preclinical models.

Recent Advances / Emerging Therapies

Recent advances in tissue engineering have accelerated the development of clinically relevant myometrial constructs. 3D bioprinting enables precise architectural replication of myometrial layers, while induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) provide autologous cell sources for differentiation into myogenic lineages. Integration of angiogenic factors and advanced bioreactors supports vascularization and functional maturation of engineered tissue. Early-phase animal studies have shown successful implantation, neovascularization, and restoration of contractility. Ongoing clinical trials are assessing the safety, integration, and reproductive outcomes of bioengineered myometrial patches in women undergoing uterine reconstruction.

Guideline Recommendations

While formal guidelines for bioengineered myometrial tissue are still evolving, leading societies such as the American Society for Reproductive Medicine (ASRM) and International Federation of Gynecology and Obstetrics (FIGO) recommend individualized assessment of uterine defects and consideration of emerging regenerative technologies within clinical trials. Multidisciplinary collaboration among reproductive endocrinologists, gynecologic surgeons, and tissue engineering experts is emphasized to optimize patient outcomes and ensure ethical implementation. Rigorous long-term follow-up and standardized outcome reporting are essential for the integration of bioengineered myometrial constructs into routine clinical practice.

Conclusion

Bioengineered myometrial tissue represents a paradigm shift in uterine reconstruction, offering the potential to restore fertility and uterine function in women with complex myometrial defects. Ongoing research and clinical translation are poised to address current limitations, with the promise of personalized, durable, and functional uterine repair. Continued multidisciplinary collaboration and evidence-based guideline development will be crucial for the safe and effective adoption of this innovative therapy in reproductive medicine.